27 January 2021 | News
Bioalpha shall fund the working capital of the procurement and distribution of the Covid-19 vaccines with internally generated funds and/or bank borrowings
Image Credit: shutterstock.com
Bioalpha International Sdn Bhd (BISB), a wholly-owned subsidiary of Bioalpha, has entered into a Procurement and Distribution Agreement with Shanghai Bukun Trading Co., Ltd (SBTC), a wholly-owned subsidiary of Sinopharm (Hainan) Health Industry Co., Ltd for the procurement and distribution of vaccines in Malaysia, including but not limited to the Covid-19 vaccine developed by Sinovac Biotech Co., Ltd., subject to relevant authorities’ approvals which include the National Pharmaceutical Regulatory Agency (NPRA). This arrangement has also been endorsed by Sinovac Biotech with regards to the Covid-19 vaccine.
The initial order volume is for 100,000 doses, with subsequent orders of up to 1 million doses.
Bioalpha shall fund the working capital of the procurement and distribution of the Covid-19 vaccines with internally generated funds and/or bank borrowings.
BISB has also entered into a Memorandum of Understanding (MOU) with Zuellig Pharma Sdn Bhd to facilitate the importation, warehousing and distribution of the Covid-19 vaccine in Malaysia.
In addition, the company has entered into a Memorandum of Understanding (MOU) with iHEAL Medical Services Sdn Bhd (iHEAL) in Malaysia, which outlines the intention of both parties to work in collaboration to provide Covid-19 vaccination services to the public.
iHEAL, through the MOH-licensed iHEAL Medical Centre, shall provide services that includes arranging on-site vaccine administration exercise with a mobile team of medical practitioners, designating a large space to undertake mass vaccination efficiently, providing a certificate of vaccination and professional consultation postvaccination, amongst others.